Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris

THOUSAND OAKS (dpa-AFX) - The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British

Related Keywords

United Kingdom ,British ,Sarah Yim ,Amgen Inc ,Office Of Therapeutic Biologics ,Alexion Pharmaceuticals ,More Such Health News ,Drug Administration ,Rare Disease ,Bkemv Risk Evaluation ,Mitigation Strategy ,Therapeutic Biologics ,Drug Evaluation ,Ihr Portfolio ,